Boceprevir With Peginterferon Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 1, 2013, Pages

  Flamm, Steven L ^a   Lawitz, Eric ^b   Jacobson, Ira ^c   Bourlière, Marc ^d   Hezode, Christophe ^e   Vierling, John M ^f   Bacon, Bruce R ^g   Niederau, Claus ^h   Sherman, Morris ⁱ   Goteti, Venkata ^j   Sings, Heather L ^j   Barnard, Richard O ^j   Howe, John A ^j   Pedicone, Lisa D ^j   Burroughs, Margaret H ^j   Brass, Clifford A ^j   Albrecht, Janice K ^j   Poordad, Fred ^k  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Alamo Medical Research   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HÔPITAL SAINT JOSEPH   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Katholische Kliniken   (Germany)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

^j MERCK RESEARCH LABORATORIES   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; PHARMACOGENOMICS; RASH; RELAPSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

EID: 84870947010     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.10.006     Document Type: Article

References (14)

1. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 2004, 140:370-381.
2. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
3. Parise E., Cheinquer H., Crespo D., et al. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis 2006, 10:11-16.
4. Goncales F.L., Vigani A., Gonçales N., et al. Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naive, relapser and non-responder patients with chronic hepatitis C. Braz J Infect Dis 2006, 10:311-316.
5. Poynard T., Colombo M., Bruix J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009, 136:1618-1628.
6. Sherman M., Yoshida E.M., Deschenes M., et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006, 55:1631-1638.
7. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
8. Poordad F., Bacon B., Bruno S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
9. Bacon B., Gordon S., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
10. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
11. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology 2010, 139:120-129.
12. Susser S., Welsch C., Wang Y., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
13. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
14. Poordad F., Bronowicki J.P., Gordon S.C., et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143:608-618.